{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-044545","form_type":"8-K","ticker":"NRXS","cik":"0001933567","company_name":"Neuraxis, INC","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.375175+00:00","generated_at":"2026-05-30T02:19:06.627816+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NeurAxis Q3 revenue up 40% to $667K; operating loss narrows 45%; secures $5M investment","bullets":["Revenue $667K, +40% YoY; unit sales +50%.","Operating loss $1.7M, improved 45% from $3.0M; net loss $1.8M, improved 80%.","Expanded insurance coverage to ~35M lives (from 4.5M); new FDA clearance for IB-Stim ages 8-21.","Received CPT Category I code for PENFS effective Jan 1, 2026.","Entered $5.0M investment agreement (closing mid-Nov), replacing prior $3.2M commitment; cash on hand $261K."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-044545","json":"https://secwatch.observer/filing/0001493152-24-044545.json","markdown":"https://secwatch.observer/filing/0001493152-24-044545.md","text":"https://secwatch.observer/filing/0001493152-24-044545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933567/000149315224044545/0001493152-24-044545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933567/000149315224044545/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:19:06.627816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}